IPP Bureau
Kahimmune Therapeutics signs agreement for scientific collaboration with Gustave Roussy
By IPP Bureau - April 29, 2026
Collaboration to accelerate mRNA neoantigen therapy development for colorectal and pancreatic cancers using advanced immunology and dark genome insights
Leinco Technologies and CellCarta partner to advance proteomics in immuno-oncology
By IPP Bureau - April 29, 2026
The combined offering is designed to support a wide range of applications, from pilot-scale research to high-volume clinical use
Sanofi Consumer Healthcare reports 33% revenue growth in Q1 FY26; PAT rises 36%
By IPP Bureau - April 29, 2026
Domestic sales increased 15.5%, supported by the relaunch of previously recalled products in the market
Gleneagles BGS Hospital launches HEAL Health Card to expand access to affordable care
By IPP Bureau - April 29, 2026
The initiative is designed to benefit patients as well as healthcare providers by streamlining access to consultations, diagnostics, and essential care services
Pfizer locks in long runway for blockbuster heart drug after key patent settlements
By IPP Bureau - April 29, 2026
The deals, tied to cases in the US District Court for the District of Delaware, effectively extend US patent protection for VYNDAMAX until June 1, 2031
Evonik and Higuchi launch “Open Pharma Lab” in Yokohama to accelerate oral drug Innovation
By IPP Bureau - April 29, 2026
EUDRAGIT polymers remain a cornerstone technology in oral drug delivery
OneSource Pharma, Dr Reddy’s secure Health Canada nod for generic Semaglutide
By IPP Bureau - April 29, 2026
Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility
Illuminova ’26 showcases AI-driven future of medical education at SRM
By IPP Bureau - April 29, 2026
SRM Medical College Hospital and Research Centre hosts undergraduate research expo highlighting innovation, interdisciplinary collaboration, and the role of artificial intelligence
Exciva initiates Phase 2/3 SERENADA trial for Alzheimer’s agitation therapy
By IPP Bureau - April 29, 2026
The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation
AbbVie seeks FDA nod for RINVOQ use in severe alopecia areata
By IPP Bureau - April 29, 2026
After Phase 3 results show major hair regrowth gains
FDA okays AstraZeneca’s triple therapy Breztri for asthma
By IPP Bureau - April 29, 2026
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
Cubo set to transform decentralised diagnostics with Compact RT-PCR innovation
By IPP Bureau - April 29, 2026
Avio Smart Market Stack Limited and Huwel Lifesciences unveil portable, cost-efficient molecular testing platform
NADMED Limited appoints James Lee as CEO to drive global expansion
By IPP Bureau - April 29, 2026
Former Novo Nordisk and Pharmanovia executive to lead next growth phase in NAD diagnostics and personalised health innovation
Laguna Diagnostics secures FDA breakthrough tag for mRNA test in psychiatric diagnosis
By IPP Bureau - April 29, 2026
The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
Granules India Q4FY26 revenue jumps 23% to Rs 14,706 million; FY26 revenue at Rs 53,656 million
By IPP Bureau - April 29, 2026
The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
